Incannex Healthcare Ltd ADR (IXHL)
Incannex Healthcare Ltd ADR (NASDAQ: IXHL) is a depositary receipt linked to Incannex Healthcare Inc., a clinical-stage biopharmaceutical company based in Sydney, Australia. Through its listed ADR, the company provides U.S. investors exposure to a developer focused on research and development of psychedelic medicines and other therapies for chronic diseases. Its pipeline includes IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide in Phase 2/3 testing for obstructive sleep apnea, and PSX-001, an oral synthetic psilocybin treatment in Phase 2b development for generalized anxiety disorder. Incannex is also advancing IHL-675A, an oral fixed-dose combination of synthetic cannabidiol and hydroxychloroquine sulphate being studied across several inflammatory and respiratory-related conditions, including rheumatoid arthritis, lung inflammation, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IXHL
|
$4.28
|
33.5% Upside
|
Undervalued
|
$17.87
|
457.5% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 29, 2026
|
-0.8x
|
0.5x
|
—
|
38.406 M
|
-35.81 M
|
0.3%
|
82.5%
|
16.1
|
—
|
36.6%
|
